AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01206257 — intervention group
Intervention type: DRUG
Intervention: Iopromide (Ultravist, BAY86-4877)
Description: Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
Study NCT01692405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviGo Bx™
Description: The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.
Study NCT01692405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy sponge pad
Description: the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
Study NCT02092922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filanesib, KSP (Eg5) inhibitor; intravenous
Description: multiple dose, single schedule
Study NCT02092922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
Description: standard of care
Study NCT04599699 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Very Low, Low, favorable, or Good Prognostic Intermediate prostate cancer:SBRT; Unfavorable, or Poor Prognostic Intermediate prostate cancer: SBRT accompanied 4 months ADT;High or Very High prostate cancer: SBRT accompanied 2 years ADT.
Study NCT01395030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FCH PET/CT
Study NCT01395030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluoromethylcholine
Description: Undergo FCH PET/CT
Study NCT01395030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FCH PET/CT
Study NCT02079766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: florbetapir F 18
Description: 370 megabecquerel (MBq) IV single-dose
Study NCT02079766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flortaucipir F18
Description: 370 megabecquerel (MBq) IV single-dose
Study NCT01658228 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Donepezil
Description: Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
Study NCT01658228 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
Study NCT01658228 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Citalopram
Description: Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.
Study NCT01658228 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venlafaxine
Description: Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.
Study NCT02348983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching via Telephone
Description: Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
Study NCT02923388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection Mecobalamin,
Description: Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
Study NCT02923388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Pyridoxine hydrochloride
Description: Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
Study NCT02923388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline 1 ml
Description: Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks
Study NCT02923388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill orally thrice daily for 5 weeks
Study NCT04510285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (8mg/kg loading dose; 6mg/kg maintenance) will be administered on day 1 of each 3-week dosing cycle (21 days).
Study NCT04510285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV will be administered on day 1 of each 3-week dosing cycle (21 days).
Study NCT01044732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Third Eye Retroscope
Description: Device used with colonoscope to provide second, retrograde view of the colon
Study NCT01044732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Third Eye Retroscope
Description: Device used with colonoscope to provide second, retrograde view of the colon
Study NCT04294108 — intervention group
Intervention type: OTHER
Intervention: Prolong in-hospital stay
Description: Patients have a longer length of hospital stay than the common recommendation.
Study NCT03365882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT03365882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT03365882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03365882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given IV
Study NCT03365882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT03365882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HER-2 testing
Description: Central testing of HER-2 for eligibility
Study NCT01101230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almonds
Description: 1.5 oz almonds/day
Study NCT01101230 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Almonds
Description: 1.5 oz almonds/day
Study NCT03487107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily
Study NCT03487107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAG181
Description: 100 mg capsule administered orally once daily
Study NCT04332627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: sugammadex 2mg/kg or 4mg/kg according to Train-of-four count (TOF 0 : 4mg/kg, TOF 1-4 : 2mg/kg)
Study NCT04332627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neostigmine
Description: with glycopyrrolate 0.4mg, neostigmine 0.02mg/kg or 0.04mg/kg or 0.05mg/kg according to Train-of-four count (TOF 0 : wait until TOF 2, TOF2-3: 0.05mg/kg, TOF4: 0.04mg/kg)
Study NCT04523818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT04523818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT04523818 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04523818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Surgical Procedure
Description: Undergo standard of care surgery
Study NCT04533022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C21
Description: C21 b.i.d.
Study NCT04329208 — intervention group
Intervention type: DEVICE
Intervention: Transcranial doppler
Description: TCD examination was performed using DWL-EZ-Dop machine Compumedics GmbH, Singen, Germany. TCD utilizes low-frequency pulsed insonation (2 MHz) to measure blood flow velocity within proximal cerebral arteries, obtaining systolic and diastolic peaks and mean flow velocities (MFV). MFV is defined as (systolic + diastolic)/3 + diastolic velocities, according to Alexandrov et al..~Initial TCD examination was done after admission serving as a baseline state for cerebral circulation. Follow-up TCD examinations was done at fixed intervals on the first, third, fifth, seventh and tenth days of the onset of SAH.
Study NCT02752126 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.
Study NCT02752126 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Esophageal-Sparing Intensity-Modulated Radiotherapy
Description: Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
Study NCT00694551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine
Description: Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
Study NCT00694551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly IC-LC
Description: Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
Study NCT01790581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
Study NCT01790581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance Training
Description: This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
Study NCT01790581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STARS
Description: The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
Study NCT04513379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz 600mg
Description: EFV 600 mg per day given orally
Study NCT04513379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz 400mg
Description: 2 tablets of EFV 200 mg per day given orally
Study NCT00219830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: home-based walking program
Description: Home-based walking program; included use of pedometer and daily walk diary
Study NCT00969800 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cleverin Gel
Description: Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
Study NCT00969800 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inactive Cleverin Gel
Description: Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
Study NCT00981357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845
Description: PF-04457845 4 mg tablet once daily / matched placebo
Study NCT00981357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg tablet twice daily / matched placebo
Study NCT01666730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin hydrochloride
Description: Given PO
Study NCT01666730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01666730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01666730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT01666730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01415778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICI176,334-1
Description: Subject will receive single dose of ICI176,334-1
Study NCT01415778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex 80 mg tablet
Description: Subject will receive single dose of Casodex 80 mg tablet
Study NCT01148095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2516
Description: Oral, single, daily, 11 days
Study NCT01148095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03968549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Those patients in group Probiotic will receive the capsules containing Lactobacillus acidophilus and will need to take one of it everyday during the study.
Study NCT03968549 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Those patients in group Placebo will receive the capsules containing vegetable oil and corn starch and will need to take one of it everyday during the study.
Study NCT03262012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI (PT010)
Description: Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
Study NCT03262012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI (PT003)
Description: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
Study NCT03262012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI (PT009)
Description: Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
Study NCT03262012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort® Turbohaler® Inhalation Powder
Description: Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
Study NCT02294812 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training.
Study NCT02294812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.~Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.~After eight weeks, participants will no longer partake in training.
Study NCT00925769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Escalating doses of 5/10mg/kg q2w
Study NCT00925769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: Escalating doses of 500/650/750/900mg/m2 bid
Study NCT00925769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: Escalating doses of 100/150mg daily
Study NCT00683293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Laparoscopic Hysterectomy
Description: Removal of uterus via standard laparoscopic techniques
Study NCT00683293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted (Da Vinci®) laparoscopic hysterectomy
Description: Removal of uterus by robot-assisted laparoscopic technique
Study NCT03380819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genome sequencing
Description: Patients will undergo exome or genome sequencing, and their referring provider will receive an interpreted report with the following categories of results: 1) results related to the indication for testing, 2) secondary monogenic results, 3) carrier status, 4) pharmacogenomics results.
Study NCT01954680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGFLEX-skill building levels
Description: COGFLEX--in English-- is a computer game designed to build up a specific skill that our work has shown is impaired in children and adolescents with bipolar disorder).~In the R33, children will be randomized to receive either COGFLEX with skill-building levels or COGFLEX-control condition which is just baseline/non-probabilistic trials.~All children will play COGFLEX twice per week for 8-weeks.~This same approach has shown great success in many psychiatric disorders including schizophrenia.~This is the first such study in children/adolescents with bipolar disorder.
Study NCT01954680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COGFLEX-control condition
Description: In the R33, the control condition will be the same COGFLEX game--but just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks.
Study NCT02684344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin may have prophylactic properties against post-operative urinary retention
Study NCT02684344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education about signs and symptoms of urinary retention
Study NCT02684344 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education about signs and symptoms of urinary retention
Study NCT00827853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional angioplasty balloon
Description: Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
Study NCT00827853 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoplasty balloon
Description: Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
Study NCT03732443 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FAM-CAM
Description: Family Confusion Assessment Method
Study NCT01434693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova
Description: single dose
Study NCT01434693 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03157856 — intervention group
Intervention type: OTHER
Intervention: Fluorescence assessment
Description: All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.
Study NCT03639311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Administered CAB LA (600 mg) Q2M, as intramuscular injection.
Study NCT03639311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV LA
Description: Administered RPV LA (900 mg), Q2M, as intramuscular injection.
Study NCT03639311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV
Description: Oral dose of RPV 25 mg, administered once daily from Day 1 up to Month 12
Study NCT03639311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG
Description: Oral dose of DTG 50 mg administered once daily from Day 1 up to Month 12.